What is BRVE's current stock price?

BRVE (Braveheart Bio, Inc.) is currently trading at $26.86 with a market cap of $1.90B.

What sector is Braveheart Bio, Inc. in?

Braveheart Bio, Inc. (BRVE) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

BRVE Braveheart Bio, Inc.

NASDAQHealthcare

$26.86-0.59%OpenMarket Cap: $1.90B

As of 2026-09-15 15:43

Why BRVE matters now

Braveheart Bio, Inc. (BRVE) is a US stock in Healthcare. The latest InvestLog snapshot shows $26.86 with -0.59% on the session and $1.90B in market capitalization.

The latest indexable market news headline is "Braveheart Bio to Participate in Stifel Cardiometabolic Forum" from GlobeNewsWire.

Latest News

Braveheart Bio to Participate in Stifel Cardiometabolic ForumGlobeNewsWire · 2026-09-16

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · 2026-09-08

Braveheart Bio to Participate in Cantor Global Healthcare ConferenceGlobeNewsWire · 2026-09-01

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?The Motley Fool · 2026-08-10

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?The Motley Fool · 2026-08-10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ

Beta

0.00

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.